Currentblue cross blue shield - kansasPolicy N/A

Charged-Particle (Proton or Helium Ion) Radiotherapy for Neoplastic Conditions

Defines medical necessity criteria, policy guidelines, and investigational exclusions for charged-particle (proton or helium ion) radiotherapy across multiple neoplastic conditions (uveal melanoma, skull-based tumors including chordoma/chondrosarcoma, pediatric CNS and non-CNS tumors, NSCLC, head and neck cancers, localized prostate cancer). Includes background, rationale, dosimetry tolerance tables, and evidence summaries.

Policy Summary

Payerblue cross blue shield - kansas

PolicyCharged-Particle (Proton or Helium Ion) Radiotherapy for Neoplastic Conditions

Policy CodePolicy N/A

Change TypeRevised (07-13-2023; edits 2024, 2025); historical coding edits

Effective DateJul 13, 2023

Next Review Date

Key ActionProvide dosimetry documentation demonstrating that conventional or advanced photon-based radiotherapy would exceed normal tissue tolerance doses when requesting coverage under Section B.

POLICY UPDATE CHANGES

07-13-2023: Added Section B listing clinical situations where charged-particle irradiation may be considered medically necessary when photon-based dose constraints cannot be met; updated Section C to list other applications considered experimental/investigational.

06-27-2024: Updated Description, Rationale, and References sections.

07-08-2025: Updated Description, Rationale, and Reference sections (dates listed in history).

Multiple historical coding and policy edits (2011-2018) altering covered/experimental listings and CPT/ICD code inclusions/removals.

3Medically necessary groups (A)

3Section B scenarios

3Experimental/investigational conditions (examples)

multipleApplications considered experimental

1Dose tolerance table (PG1)

7Key proton/procedure codes listed

Coverage Summary

This policy (effective 2023-07-13, last reviewed 2025-07-08) defines medical necessity criteria, policy guidelines, and investigational exclusions for charged-particle (proton or helium ion) radiotherapy across multiple neoplastic conditions. It covers specific indications (eg, uveal melanoma, skull‑based chordoma/chondrosarcoma, pediatric CNS tumors) and includes requirements for dosimetry documentation and dose‑volume tolerance thresholds (see Policy Guidelines/Table PG1).

The coverage stance is mixed: the policy identifies explicit medically necessary indication groups (Section A and Section B when photon planning cannot meet normal‑tissue constraints) while designating several other applications as experimental/investigational (Section C). High‑level takeaways: clinically necessary indications include uveal melanoma (with tumor size limits), skull‑base postoperative therapy for chordoma/chondrosarcoma, and pediatric CNS tumors (Section A); Section B lists scenarios that are medically necessary only when photon-based dose‑volume constraints cannot be met (curative pediatric non‑CNS solid tumors, curative nonmetastatic NSCLC, head & neck cancers); Section C lists other uses (eg, localized prostate cancer, non‑curative pediatric/non‑CNS applications, non‑curative NSCLC) as experimental/investigational.

Key thresholds & quick facts

Uveal melanoma largest diameter threshold<= 24 mm

Uveal melanoma height threshold<= 14 mm

Medically necessary A groups (explicit listed)3 groups (uveal melanoma; postsurgical skull‑base chordoma/chondrosarcoma; pediatric CNS tumors)

Medically necessary scenarios (Section B) count3 scenarios (curative pediatric non‑CNS solid tumors including Ewing sarcoma; curative nonmetastatic NSCLC; head & neck cancers)

Dose tolerance table present (Table PG1)Yes — radiation tolerance thresholds for organs at risk included (Table PG1)

Medical-Necessity Criteria

Medically Necessary Indications (Section A)

Charged-particle irradiation with proton or helium ion beams may be considered medically necessary in the following clinical situations:

ALL of the following

Tumor-specific limits
- No evidence of metastasis or extrascleral extension
- Tumors up to 24 mm in largest diameter<= 24 mm
- Tumors up to 14 mm in height<= 14 mm

Not Covered / Experimental

Experimental / Investigational Indications (Section C)

Other applications are considered experimental / investigational, including but not limited to:

ANY of the following

Clinically localized prostate cancer
Non-curative treatment of primary or benign solid pediatric non-central nervous system tumors, including Ewing sarcoma
Non-curative treatment of non-small cell lung cancer

Other Applications - Experimental/Investigational

Other applications of charged-particle irradiation with proton or helium ion beams are considered experimental/investigational (includes but not limited to):

Coding

Specific proton treatment delivery and related CPT/HCPCS codes (informational; medically necessary only if performed per Policy section)CPT|HCPCS

77299	Unlisted procedure, therapeutic radiology clinical treatment planning.
77399	Unlisted procedure, medical radiation physics, dosimetry and treatment devices, and special services.
77499	Unlisted procedure, therapeutic radiology treatment management.
77520	Proton treatment delivery; simple, without compensation.
77522	Proton treatment delivery; simple, with compensation.
77523	Proton treatment delivery; intermediate.
77525	Proton treatment delivery; complex.

Stereotactic charged particle radiosurgery codes (historical removals)CPT|HCPCS

61796	Stereotactic radiosurgery; cranial lesion (code removed from coding section historically).
61797	...
61798	...
61799	...
63620	...
63621	...

Provider Actions & Billing

Prior Authorization

Medical necessity requirement

Verify member benefits prior to scheduling. Services must meet the medical necessity criteria described in Sections A and B of the policy to be eligible for coverage.

Documentation Required

Dosimetry documentation when photon constraints exceeded

When a photon-based plan would exceed normal-tissue dose constraints, provide complete dosimetry documentation including treatment planning CT, dose–volume histograms (DVHs), and exported plan files demonstrating doses to target and organs at risk. Reference Table PG1 for standard organ-at-risk tolerance thresholds.

Provide treatment planning CT and dosimetry reports (DVHs).
Include dose distributions and target coverage metrics.
Reference Table PG1 for organ-at-risk tolerance thresholds.

Background & Evidence

Charged‑particle beams (protons or helium ions) deliver high radiation doses with minimal scatter and depth‑specific energy deposition (the Bragg peak), which can minimize dose to surrounding normal tissues and critical structures and may improve outcomes when photons cannot provide adequate local control or when vital radiosensitive structures limit tumor dosing.

Regulatory note: while radiotherapy as a procedure is not an FDA‑regulated therapy, the accelerators and delivery equipment used for charged‑particle radiation (eg, proton therapy systems and accessories) are medical devices subject to FDA oversight (eg, 510(k) clearances for delivery systems and accessories).

Evidence Summary

Revision History

10-06-2011coding/policy_update

Policy added to bcbsks.com web site.

08-06-2013policy_revision

Added pediatric CNS tumors to Item A and revised Item C to include clinically localized prostate cancer, pediatric non-CNS tumors, and head and neck tumors (other than skull-based); added ICD-9 codes and updated Rationale and References.

12-11-2013coding_update

Added ICD-10 diagnosis codes (effective October 1, 2014) and updated References; subsequent coding and policy wording changes through 2015 removed/noted prostate cancer language and reorganized investigational listings.

Policy Summary

Payerblue cross blue shield - kansas

PolicyCharged-Particle (Proton or Helium Ion) Radiotherapy for Neoplastic Conditions

Policy CodePolicy N/A

Change TypeRevised (07-13-2023; edits 2024, 2025); historical coding edits

Effective DateJul 13, 2023

Next Review Date

Key ActionProvide dosimetry documentation demonstrating that conventional or advanced photon-based radiotherapy would exceed normal tissue tolerance doses when requesting coverage under Section B.

On This Page

Postoperative therapy (with or without conventional high-energy x-rays) in individuals who have undergone biopsy or partial resection of chordoma, or low-grade (I or II) chondrosarcoma of the basisphenoid region (skull-based chordoma or chondrosarcoma) or cervical spine

Individuals eligible have residual localized tumor without evidence of metastasis

Pediatric central nervous system tumors

Medically Necessary When Photon Planning Cannot Meet Dose-Volume Constraints (Section B)

Charged-particle irradiation may be considered medically necessary where treatment planning with conventional or advanced photon-based radiotherapy cannot meet dose-volume constraints for normal tissue radiation tolerance:

ANY of the following

Curative treatment of primary or benign solid pediatric non-central nervous system tumors, including Ewing sarcoma
Curative treatment of nonmetastatic primary non-small cell lung cancer
Head and neck cancers

Condition: Documentation with dosimetry plans demonstrating conventional or advanced photon-based radiotherapy would exceed tolerance doses to structures at risk (see Policy Guidelines / Table PG1)See Table PG1

Clinical documentation based on dosimetry plans required to demonstrate inability of photon plans (eg, IMRT, VMAT, SRS, SBRT) to meet dose-volume constraints.

Policy Clinical Applications (as amended 07-13-2023)

Charged-particle irradiation with proton or helium ion beams may be considered medically necessary where photon-based radiotherapy cannot meet dose-volume constraints for normal tissue radiation tolerance in the following clinical situations:

ONE of

Curative treatment of primary or benign solid pediatric non-central nervous system tumors, including Ewing sarcoma.
Curative treatment of nonmetastatic primary non-small cell lung cancer.
Head and neck cancers (other than skull-based chordoma or chondrosarcoma).

Clinically localized prostate cancer (listed historically as investigational in prior versions; policy language has changed over time—see coding history).

Non-curative treatment of primary or benign solid pediatric non-central nervous system tumors, including Ewing sarcoma.

Non-curative treatment of non-small cell lung cancer.

Documentation Required

Demonstrate inability of photon-based plan to meet dose-volume constraints

Document a clear comparison showing that optimized photon-based techniques (including IMRT/VMAT/SRS/SBRT) could not meet the dose–volume constraints for critical structures. Include side-by-side dosimetric comparisons (photon plan vs proton plan) and a statement tying the inability to meet constraints to the Section B criteria for medical necessity.

Submit comparative photon and charged-particle treatment plans and DVHs.
Provide a clinician statement that photon plans could not meet Section B dose‑volume constraints.

Documentation Required

Pediatric indication age documentation

For pediatric indications, document the patient’s age (must be <21 years) in the medical record and include any supporting evidence regarding pediatric diagnosis and treatment rationale. Note Policy Guidelines on age distributions and expert guidance for pediatric patients.

Record patient age and date of birth in submitted documentation.
Include clinical rationale for pediatric use and any relevant evidence or specialist notes regarding age-related benefit.

Billing Rule

Use specific proton CPT/HCPCS codes for billing

Report applicable proton therapy procedure codes on claims when performed per policy. Use specific unlisted/procedure codes as appropriate and include charges only for services rendered.

CPT/HCPCS: 77299, 77399, 77499, 77520, 77522, 77523, 77525
Report these codes when the corresponding proton therapy services are performed per this policy.

04-12-2017policy_revision

Removed clinically localized prostate cancer from Item B and added new Item C stating clinically localized prostate cancer is considered not medically necessary; added 'or helium ion' language and updated Policy Guidelines.

08-29-2018coding_update

Removed ICD-9 codes from Coding section and updated Description, Rationale, and References.

07-13-2023material_policy_change

06-27-2024update

06-27-2024: Updated Description, Rationale, and References sections.

07-08-2025updateLatest

07-08-2025: Updated Description, Rationale, and Reference sections (dates listed in history).

2011-2018material_coding_history

Multiple historical coding and policy edits (2011-2018) altering covered/experimental listings and CPT/ICD code inclusions/removals; examples include removal/addition of prostate cancer from various sections, removal of ICD-9 codes, and addition/removal of stereotactic procedure codes. (Material change)